Aurobindo Pharma receives USFDA final approval for Bivalirudin Injection

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection, 250 mg/vial. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax Injection of The Medicines Company.

The estimated market size of Bivalirudin injection is US$ 101 million for the twelve months ended May 2018 according to IQVIA. The product will be launched in September 2018.

Powered by Capital Market - Live News